Smoking Rates Among Australian Adults Decline in Last Decade.

Dec.05.2022
Smoking Rates Among Australian Adults Decline in Last Decade.
10% of Australian adults smoke daily with the average age increasing to 46; youth smoking rates have decreased drastically.

According to the Australian Bureau of Statistics, approximately 1 in 10 adults (approximately 1.9 million people) have been identified as regular daily smokers of one or more cigarettes, cigars, or e-cigarettes.


Overall, the proportion of adults who smoke daily has decreased over the past decade, dropping from 16.1% in 2011-2012 to 10% in 2021.


People aged 18 to 44 report that the proportion of daily smokers has almost halved.


The average age of those identified as daily smokers has increased nationwide.


In 2021, the average age for smoking is 46, which is higher than 42 a decade ago.


The daily number of smokers has decreased in all age groups except for those aged between 55-64 and those aged 65 and above.


During the same period, the proportion of young people aged 18 to 24 who smoke daily has decreased by half, from 16.5% in 2011-2012 to 7.1% in 2021-22.


In the 2021-2022 school year, the majority of young people between the ages of 15 and 17 (96.8%) are currently non-smokers, which is higher than the rate of 94.2% from a decade ago.


However, the analysis excluded people who use electronic cigarettes (including vaping), smokeless tobacco, and non-tobacco smoking products.


It has been found that men are more likely than women to be current daily smokers, with a prevalence of 12% compared to 8.2%.


In statistical terms, adults born in Australia are more likely to smoke. Nearly one-fifth (18.6%) of unemployed individuals currently smoke on a daily basis.


Overall, the smoking population in these areas has decreased from 23.4% to 16.1% per day as of 2021-2022.


2FIRSTS will continue to track and report on this topic, with updates to be found on the '2FIRSTS APP'. Scan the QR code below to download the app.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
Special Report|From Nicotine Pouches to Jelly? A China Tobacco Patent Explores Dual-Release NRT
A patent published on February 24, 2026, by China Tobacco Hubei Industrial Co., Ltd. introduces a “nicotine jelly” product designed to combine rapid and sustained nicotine delivery. By integrating both free and microencapsulated nicotine, the product aims to address key limitations of traditional nicotine replacement therapy (NRT), while also raising new regulatory and product classification questions.
Innovation
Mar.18
Philip Morris Korea Launches New IQOS ILUMA i “Electric Purple” Color Edition
Philip Morris Korea Launches New IQOS ILUMA i “Electric Purple” Color Edition
Philip Morris Korea said it has launched a new color edition of its heated tobacco device brand IQOS, called “IQOS ILUMA i Electric Purple.” The new color has been added to the IQOS ILUMA i series and applies to the Prime, standard, and One variants. The product is being sold through the IQOS website and nine IQOS directly operated stores across South Korea.
Mar.12 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
West Virginia House passes “Vape Safety Act of 2026,” creating licensing and product directory requirements
West Virginia House passes “Vape Safety Act of 2026,” creating licensing and product directory requirements
West Virginia’s House of Delegates passed the Vape Safety Act of 2026, a proposal to tighten oversight of vape and smoke shops through licensing, fees and enforcement. The bill would establish a state directory requiring vape products sold in West Virginia to have FDA marketing authorization or a pending application under FDA review to be listed, and only directory-listed products could be sold starting Sept. 1, 2026 if enacted.
Feb.28 by 2FIRSTS.ai
BENDSTA Urges Prime Minister to Review Bangladesh’s 2025 Tobacco Control Ordinance
BENDSTA Urges Prime Minister to Review Bangladesh’s 2025 Tobacco Control Ordinance
The Bangladesh Electronic Nicotine Delivery System Traders Association (BENDSTA) has urged the prime minister to initiate a comprehensive parliamentary review of the Smoking and Tobacco Products Use (Control) Ordinance, 2025.
Mar.12 by 2FIRSTS.ai
Pakistan Senate health panel weighs possible vape ban
Pakistan Senate health panel weighs possible vape ban
Sources say Pakistan’s Senate Standing Committee on Health is deliberating whether to impose a ban on vaping products, after holding a meeting on the health implications of vaping and the rising use of e-cigarettes nationwide.
Mar.04 by 2FIRSTS.ai